Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
Evans
Christopher P
CP
Department of Urology, University of California, Davis, School of Medicine, Sacramento, CA, USA. christopher.evans@ucdmc.ucdavis.edu
D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage* / Q000627:therapeutic use; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D016685:Mitomycin